BioArctic

324.20 SEK

+2.92 %

Less than 1K followers

BIOA B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+2.92 %

-1.46 %

+4.31 %

+9.97 %

+36.10 %

+52.64 %

+18.32 %

+228.47 %

+1,017.93 %

BioArctic is a biopharmaceutical company focused on developing new treatments that address the causes of neurodegenerative diseases. Examples of diseases include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. BioArctic was founded in 2003 and is headquartered in Stockholm.

Market cap

28.74B SEK

Turnover

68.92M SEK

Revenue

257.35M

EBIT %

-88.79 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

18.2

2026

Annual report '25

20.5

2026

Interim report Q1'26

28.5

2026

General meeting '26

All

Webcasts

Press releases

ShowingAll content types

Press release2/13/2026, 12:30 PM

Modular Finance IR Consensus: BioArctic – Consensus estimates Q4 2025

Press release2/11/2026, 7:30 AM

Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET

Regulatory press release2/9/2026, 5:45 AM

BioArctic: BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release2/6/2026, 11:00 AM

BioArctic: Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025

Regulatory press release1/26/2026, 9:00 PM

BioArctic: Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)

Regulatory press release1/25/2026, 11:30 PM

BioArctic: Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

BioArctic, Audiocast, Q4'25

Webcast2/18/2026, 8:30 AM

BioArctic, Audiocast, Q4'25

Regulatory press release1/6/2026, 11:00 AM

BioArctic: BLA for subcutaneous formulation of Leqembi® accepted in China

Press release12/8/2025, 11:30 PM

BioArctic: Leqembi included in China's commercial insurance innovative drug list

Press release12/4/2025, 6:45 AM

BioArctic: New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment

Regulatory press release11/28/2025, 5:30 PM

Number of shares and votes in BioArctic AB (publ) as of November 28, 2025

Regulatory press release11/28/2025, 5:30 AM

BioArctic: New drug application for subcutaneous formulation of Leqembi[®] submitted in Japan

Regulatory press release11/25/2025, 12:37 PM

BioArctic: Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose

Press release11/18/2025, 11:30 PM

BioArctic: New data on lecanemab to be presented at CTAD conference

Press release11/18/2025, 10:32 AM

Redeye: BioArctic (Q3 Review) - Stable progress

Press release11/13/2025, 11:30 PM

BioArctic: Leqembi® approved for IV maintenance treatment in the United Kingdom

BioArctic, Audiocast, Q3'25

Webcast11/13/2025, 8:30 AM

BioArctic, Audiocast, Q3'25

Regulatory press release11/13/2025, 7:00 AM

BioArctic: Interim Report for the period July - September 2025

Press release11/10/2025, 2:00 PM

Modular Finance IR Consensus: BioArctic – Consensus estimates Q3 2025

Press release11/4/2025, 9:00 AM

Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET

Forum discussions

If you are investing in a company whose goal is to find cures for diseases such as Alzheimer’s, Parkinson’s, and ALS, BioArctic is the right investment for you, as this company’s ambitions are certainly not lacking. In addition, there is evidence, as a drug called Lecanemab has actually...

8/28/2025, 10:21 AM

by Hawkmountdiver

7

About that valuation. What has been the share price development in recent years? A quick read suggests it looks good. If compared to Faron and Herantis companies, this is a safer investment target at this moment.

8/28/2025, 2:16 PM

by j.sälli

2

Brand new Q2 / 2025 below. bioarctic.com wkr0006-146.pdf 1682.08 KB

8/28/2025, 10:28 AM

by Hawkmountdiver

0

Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.